Literature DB >> 12432215

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia.

David J Barnes1, Junia V Melo.   

Abstract

Chronic myeloid leukaemia (CML) is caused by the product of the BCR-ABL oncogene, located on the Philadelphia (Ph) chromosome. BCR-ABL is generated as a result of a reciprocal t(9;22) chromosomal translocation. The mechanisms responsible for this illegitimate recombination event remain elusive but are presumed to require a close spatial association of the translocation partners (chromosomes 9 and 22). BCR-ABL fusion transcripts can be detected by a sensitive reverse transcription-polymerase chain reaction (RT-PCR) in the leucocytes of some healthy individuals suggesting that chromosomal translocations may occur frequently in the general population. The presence of BCR-ABL fusion transcripts does not imply that the individual will inevitably develop CML since other conditions must be favourable for expansion of the abnormal clone. Breakpoints in the ABL gene occur within a 5' segment. BCR-ABL fusion transcripts lack ABL exon a1 and consist of BCR exons fused directly to ABL exon a2. The breakpoints in the BCR gene on chromosome 22 are found within three defined regions. Depending on the position of the BCR breakpoint, fusion genes are generated that encode 190-, 210- or 230-kD forms of the Bcr-Abl tyrosine kinase. Since the ABL component of the fusion gene is largely invariant, it follows that variability in disease phenotype may be due to protein sequences encoded by the translocation partner, BCR. Different disease phenotypes are associated with each of the three Bcr-Abl oncoproteins, p190(Bcr-Abl), p210(Bcr-Abl )and p230(Bcr-Abl). Mechanisms associated with malignant transformation include altered cellular adhesion, activation of mitogenic signalling pathways, inhibition of apoptosis and proteasomal degradation of physiologically important cellular proteins. CML is subject to an inexorable progression from an 'indolent' chronic phase to a terminal blast crisis. Disease progression is presumed to be associated with the phenomenon of genomic instability. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432215     DOI: 10.1159/000065655

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  16 in total

Review 1.  Polycomb group proteins in hematopoietic stem cell aging and malignancies.

Authors:  Karin Klauke; Gerald de Haan
Journal:  Int J Hematol       Date:  2011-04-27       Impact factor: 2.490

2.  Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Authors:  Xiaomin Zheng; Claudia Oancea; Reinhard Henschler; Malcolm A S Moore; Martin Ruthardt
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

3.  How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review.

Authors:  Lin-Hui Hu; Lian-Fang Pu; Dong-Dong Yang; Cui Zhang; Hui-Ping Wang; Yang-Yang Ding; Man-Man Li; Zhi-Min Zhai; Shudao Xiong
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

4.  A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.

Authors:  Natini Jinawath; Alexis Norris-Kirby; B Douglas Smith; Christopher D Gocke; Denise A Batista; Constance A Griffin; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2009-06-04       Impact factor: 5.568

Review 5.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

6.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

7.  A stochastic model of oncogene expression and the relevance of this model to cancer therapy.

Authors:  Francis D Alfano
Journal:  Theor Biol Med Model       Date:  2006-01-31       Impact factor: 2.432

8.  Development and targeted use of nilotinib in chronic myeloid leukemia.

Authors:  Carmen Fava; Hagop Kantarjian; Jorge Cortes; Elias Jabbour
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

9.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

10.  The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Anahita Rafiei; Afsar Ali Mian; Claudia Döring; Anna Metodieva; Claudia Oancea; Frederic B Thalheimer; Martin Leo Hansmann; Oliver Gerhard Ottmann; Martin Ruthardt
Journal:  PLoS Genet       Date:  2015-04-28       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.